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Abstract A protein kinase activity intrinsic to the sarcoplasmic
reticulum was studied in normal and hypertrophied rabbit hearts.
The relationship between this kinase activity and phospholamban
phosphorylation was examined. Calmodulin-dependent kinase II
activity was found to be increased in sarcoplasmic reticulum
preparations from hypertrophied hearts compared with normal.
This was evident by measuring the phosphotransferase activity of
the kinase and also by examining phospholamban phosphoryla-
tion by electrophoretic band shift analysis. Increased phospho-
lamban phosphorylation by Calmodulin-dependent protein kinase
II was dependent on prior phosphorylation by cAMP-dependent
protein kinase, indicating potential crosstalk. Specific immuno-
blot analysis of the rabbit sarcoplasmic reticulum identified the
presence of the N form of calmodulin dependent protein kinase II
and showed it to be up-regulated in hypertrophied hearts.
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1. Introduction
Ca2 release and re-uptake by the sarcoplasmic reticulum
(SR) is tightly regulated in mammalian heart and is critical for
systolic and diastolic function. In failing heart these functions
are compromised. Alterations in Ca2 uptake in failing heart
have been suggested to be a result of altered Ca2 pump
(SERCA 2) activity and/or expression [1,2]. Since activity of
the pump is regulated by phospholamban (PLB), numerous
studies have focused on the properties of this protein and the
factors that may govern it. Previous work has demonstrated
that PLB can be phosphorylated at two sites, serine 16 by
cAMP-dependent protein kinase (PKA) and threonine 17 by
calmodulin dependent protein kinase II (CaM kinase II). PLB
in the dephosphorylated state acts as an inhibitor of SERCA
2. Phosphorylation by the kinases mentioned above relieves
this inhibition and the process of active Ca2 transport into
the SR lumen is enhanced.
CaM kinase II is a member of a ubiquitous family of Ca2/
calmodulin regulated enzymes. Four isoforms derived from
four closely related genes (K, L, Q and N) have now been
identi¢ed [3]. Members of the K and L classes are expressed
only in neuronal tissues. However, Q and N isoforms are also
expressed in non-neuronal tissues [4,5]. Previous work on por-
cine myocardium has suggested that the SR associated kinase
which phosphorylates PLB is of the N family [6].
Although it is largely understood how PLB phosphoryla-
tion occurs under normal conditions, little information exists
concerning protein phosphorylation in cardiomyopathic con-
ditions and the studies that have been performed to date are
often contradictory. Previous work by our group has sug-
gested that in the rabbit coronary artery ligation model there
is evidence of increased PLB phosphorylation when compared
with sham-operated animals [7]. This e¡ect seems to be evi-
dent at both serine and threonine sites as observed with phos-
phorylation site-speci¢c antibodies. In the present study we
have examined the possibility that there is increased kinase
activity associated with the SR in our experimental hearts
that may account for these observations. We have demon-
strated for the ¢rst time that SR preparations made from
hypertrophic remodelled myocardium adjacent to the infarct
site, have increased CaM kinase activity which may, either
alone or in co-operation with PKA, lead to increased PLB
phosphorylation. Using CaM kinase isoform-speci¢c antibod-
ies, we have identi¢ed that N CaM kinase is prevalent in SR
isolated from these rabbit hearts. This may be the isoform
responsible for the increased activity observed in these prep-
arations.
2. Materials and methods
2.1. Preparation of animals
New Zealand white male rabbits aged 12 weeks and weighing ap-
proximately 3 kg were used for experiments. Animals were anaesthe-
tised with hypnorm and maintained with halothane and nitrous oxide/
oxygen. A left thoracotomy was performed and the large circum£ex
branch of the left coronary artery was identi¢ed and ligated. Sham-
operated animals went through the same procedure but the artery was
not tied. Animals were left for 8 weeks to allow cardiac remodelling to
occur. Echocardiography of left ventricular function was assessed and
ejection fractions ranged from 67^77% for sham-operated animals and
from 28^52% for coronary artery ligated animals, with means of
73.0 þ 1.3% and 43.1 þ 2.8% respectively (n = 14). These values are
very similar to previously published data on this model [8]. In coro-
nary artery ligated animals there was signi¢cant haemodynamic dys-
function. There was evidence of hypertrophy indicated by increased
heart weights and evidence of congestion since both lung and liver wet
weights were increased on post-mortem examination [9]. Overall, these
results suggest that the coronary artery ligation model produces a
signi¢cant degree of heart failure in these animals.
Prior to experiments, rabbits were given a lethal injection of pento-
barbital sodium (100 mg/kg) and hearts were rapidly removed and
washed several times in modi¢ed Krebs solution [150 mM NaCl,
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5 mM KCl, 2 mM CaCl2, 1 mM MgCl2, 5 mM 4-[2-hydroxyethyl]-1-
piperazine-ethanesulphonic acid (HEPES), pH 7.0, 10 mM glu-
cose].
2.2. Isolation of SR
The preparation of SR was based on a previously reported method
[10]. The isolated free wall of the left ventricle (1^2 g of tissue) was
removed, minced using ¢ne scissors and then homogenised using an
ultraturrax (Labortechnik) in ice-cold homogenisation bu¡er [0.3 M
sucrose, 10 mM imidazole, pH 7.0, 30 mM histidine, 1 mM dithio-
threitol (DTT), 1 mM phenylmethylsulphonyl £uoride (PMSF), 1 Wg/
ml leupeptin and 100 Wg/ml aprotinin). The homogenate was centri-
fuged to remove large particles and was then further processed by
several high speed centrifugation and precipitation steps to yield the
crude SR preparation as described previously [7]. This was either
stored in precipitation bu¡er (same composition as homogenisation
bu¡er but with 0.6 M KCl) at 370‡C or prepared in assay bu¡er for
immediate use.
2.3. PLB phosphorylation studies
SR preparations (50 Wg) were incubated at 30‡C for the appropriate
times in the presence of 2 mM ATP and presence or absence of added
calmodulin and calcium at ¢nal (free) concentrations of 0.6 and
1.25 WM, respectively in assay bu¡er containing protease and phos-
phatase inhibitors [11]. In experiments examining the e¡ect of dual
phosphorylation, preparations were incubated for 2 min with 0.2 WM
catalytic subunit of PKA (Boehringer Mannheim) prior to addition of
calcium and calmodulin. In experiments where the CaM kinase inhib-
itor peptide (281^301) (Calbiochem) was used it was added for the
indicated times at 20 WM. Reactions were left to proceed for the
appropriate times and were terminated by the addition of 4ULaemmli
sample bu¡er (6% SDS, 30% glycerol, 235 mM Tris, pH 6.8, 0.005%
bromophenol blue, 8 mM L-mercaptoethanol). These were stored fro-
zen until analysis.
2.4. CaM kinase activity assay
The assay was designed to measure the phosphotransferase activity
of CaM kinase II in crude preparations and was based on phospho-
rylation of speci¢c substrate peptide (KKALRRQETVDAL) by the
transfer of Q-phosphate of [Q-33P]ATP (DuPont NEN; 1000^3000 Ci/
mmol) by the CaM kinase. Activity was measured in SR preparations
made at approximately 2^5 mg/ml in assay dilution bu¡er (20 mM
3-[N-morpholino]propanesulphonic acid (MOPS), pH 7.2, 25 mM
L-glycerophosphate, 1 mM Na3VO4, 1 mM DTT, 1 mM CaCl2).
The ¢nal protein content in each assay sample was between 20^50
Wg. Assay components (from a kit supplied by Upstate Biotechnology)
were mixed on ice and reactions initiated by addition of the
[33P]Mg2/ATP (25WCi/100Wl). Incubations were performed at 30‡C
for the required times and reactions stopped by transferring to P81
phosphocellulose paper. These papers were washed ten times in 0.75%
phosphoric acid to remove residual radioactivity and twice in acetone
to aid drying. The bound phosphorylated substrate was then quanti-
tated by scintillation counting.
2.5. Electrophoresis and immunoblotting
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) was performed as previously described [12] using the Novex
system with either 10% or 14% Tris-glycine gels for CaM kinase and
PLB detection, respectively. As with previous studies by our group,
samples prepared for electrophoresis were not heated and hence, there
was no degradation of the pentameric 25 kDa form of PLB into the
monomer V5 kDa. Gels were subjected to electrophoresis at a con-
stant current of 25 mA for 1.25 h for PLB and 1.75 h for CaM kinase.
Proteins were transferred to nitrocellulose membranes and these were
then blocked in a BSA blocking bu¡er [7]. Blots were incubated over-
night at 4‡C with mouse anti-PLB monoclonal antibody A1* (0.0625
Wg/ml) and/or PT-17 (1:5000 dilution) (Phosphoprotein Research) or
with rabbit anti-N CaM kinase (0.5 Wg/ml) (gift from Dr P. Karczew-
ski, Berlin) or goat anti-Q CaM kinase (0.05 Wg/ml) (Santa Cruz).
Membranes were washed and then incubated for 2 h at room temper-
ature with either goat anti-mouse IgG-horseradish peroxidase conju-
gate diluted 1:2000 (Transduction laboratories), goat anti-rabbit IgG-
horseradish peroxidase conjugate diluted 1:5000 (Jackson Immuno-
Research)or mouse anti-goat IgG-horseradish peroxidase conjugate
diluted 1:4000 (Santa Cruz), for PLB and CaM kinase N and Q, re-
spectively. The blots were then washed a further three times and
developed using the ECL detection system (Amersham).
2.6. CaM kinase antibody preparation
Anti-N speci¢c antibodies were raised in rabbits as previously de-
scribed [13]. Brie£y, the antigenic epitope KENFSGGTSLWQNI cor-
responding to the C terminus for a subclass of isoforms of N CaM
kinase from rat was used. Peptide conjugation and immunisation was
performed as previously described [14] and the resulting polyclonal
antibodies were a⁄nity puri¢ed on peptide a⁄nity columns [15]. Ali-
quots of the N antibody were kindly provided by Dr P. Karczewski
(Max Delbru«ck Centre for Molecular Medicine, Robert Ro«ssle StraMe
10, Berlin, Germany). Goat polyclonal anti-Q CaM kinase antibodies
were raised against an epitope mapping at the C-terminus of Q CaM
kinase II of human origin (Santa Cruz).
2.7. Protein measurements
Protein content was determined using the Coomassie Plus protein
assay (Pierce) and BSA (0.1^1 mg/ml) as standards.
3. Results and discussion
Initial experiments examining changes in intrinsic phos-
phorylation levels of PLB using SR preparations were per-
formed as previously described [7]. Upon addition of ATP
and using electrophoretic band shift analysis, we observed
increased phosphorylation of PLB in experimental hearts
over a 5 min period of incubation (Fig. 1). These results in-
dicate the potential existence of elevated kinase activity intrin-
sic to the SR.
Assessment of CaM kinase II activity associated with the
SR was then made using an assay kit (Upstate) designed to
speci¢cally measure activity of this enzyme in crude prepara-
tions. We examined phosphotransferase activity in fresh SR
preparations over a period of 10 min incubation with a spe-
ci¢c substrate peptide (see Section 2) and in the presence of
inhibitors for PKA and PKC. Results indicated that CaM
kinase activity was higher in preparations from coronary ar-
tery ligated rabbit hearts compared with sham-operated ani-
mals (mean activity over background was 842 þ 186 cf.
346 þ 48 pmol phosphate inc./min/mg protein from four ex-
Fig. 1. Comparison of intrinsic PLB phosphorylation in experimen-
tal and sham-operated preparations. SR preparations were incu-
bated at 30‡C for the indicated times in the presence of ATP. Reac-
tions were stopped by the addition of 4ULaemmli sample bu¡er
and 10 Wg samples were subjected to electrophoresis as described.
PLB was detected using the A1 antibody which detects both phos-
phorylated and dephosphorylated forms of PLB. This experiment is
representative of six others.
* The A1 antibody can detect both de-phosphorylated and phos-
phorylated (P1^P10) forms of PLB. PT-17 detects the threonine phos-
phorylated form of PLB.
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perimental and four sham-operated animals, respectively)
(Fig. 2). Moreover, we performed some preliminary experi-
ments to measure activity in crude cell lysates and also found
that to be slightly elevated in preparations from experimental
animals. Since this assay is linear with time up to 30 min, we
did test a number of other incubation times (shorter and lon-
ger) and found that the optimal di¡erence in activity was
observed between 5^10 min incubation. In parallel with these
studies, we also examined whether there was an increase spe-
ci¢cally in the threonine phosphorylated form of PLB. These
measurements were made using phosphoamino acid speci¢c
antibodies against the Thr-17 form of PLB. Results suggest
that in experimental preparations, along with an increase in
CaM kinase II activity, there is a corresponding increase in
threonine phosphorylated PLB (Fig. 2.).
In a further attempt to link this observed increase in CaM
kinase activity with a potential increase in PLB phosphoryla-
tion, we performed time course experiments on SR prepara-
tions under conditions that had been manipulated to favour
activation of either PKA or CaM kinase or both. Using band
shift analysis which allows observation of up to 10 di¡erent
phosphorylation states of PLB with the PLB speci¢c A1
monoclonal antibody, we were able to detect changes in the
levels of phosphorylation of PLB after selective stimulation of
these kinases. In the absence of any added PKA, the e¡ect of
added Ca2 and CaM was examined in sham and experimen-
tal preparations (Fig. 3a). As observed in our previous studies,
the overall levels of phosphorylation achieved by intrinsic
kinase activity over time were higher in the experimental prep-
arations. However, the addition of Ca2 and CaM had no
obvious additional e¡ect on phosphorylation in either sham
or experimental preparations. Since previous studies had in-
dicated the possibility that in some preparations, serine phos-
phorylation by PKA may be a pre requisite for stimulation of
threonine phosphorylation by CaM kinase, we decided to ex-
amine this possibility. We tested whether prior phosphoryla-
tion with a sub-optimal dose of PKA might boost activation
of intrinsic SR CaM kinase activity and lead to further PLB
phosphorylation. SR preparations were treated with 0.2 WM
PKA for increasing times and compared with preparations
that had been pre-treated with PKA for 2 min and then
Ca2 and CaM added for increasing periods. Since sub-opti-
mal levels of PKA were added to these preparations, phos-
phorylation in the presence of PKA alone, was fairly slow (cf.
a complete band shift to P5 was observed when SR prepara-
tions were treated for 10 min with 2 WM PKA, unpublished
observations). However, when the same preparations were
pre-treated with PKA and then had Ca2 and CaM added,
there was an obvious increase in the number of phospho-
Fig. 2. Measurement of CaM kinase II activity associated with the
SR and comparison with Thr-17 phosphorylation of PLB. a: Prepa-
rations were made from sham-operated and hypertrophied (experi-
mental) myocardium as described. Phosphotransferase activity of
CaM kinase II was measured after 10 min incubation with a speci¢c
substrate peptide as described in the Section 2. Data represent the
mean þ S.E.M. of four sham and four experimental animals. b: The
Thr-17 phosphorylated form of PLB was detected using a phos-
phoamino acid speci¢c antibody (PT-17) against PLB. SR prepara-
tions (10 Wg) from a time course experiment (as described for Fig.
1.) were subjected to electrophoresis as described. This experiment is
representative of four others.
Fig. 3. E¡ect of added Ca2 and calmodulin in the presence or ab-
sence of PKA pre-treatment on PLB phosphorylation. a: SR prepa-
rations were incubated at 30‡C for increasing times in the presence
of ATP and the presence or absence of added Ca2/CaM for the in-
dicated times. b: Preparations were incubated as before but for in-
creasing times in the presence of a sub-optimal level of PKA (0.2
WM). The e¡ect of subsequent addition of Ca2/CaM was tested at
increasing times of incubation as indicated. Reactions were termi-
nated by addition of 4ULaemmli sample bu¡er and subjected to
electrophoresis as described. PLB was detected using the A1 anti-
body as before. Results are from a single experiment, representative
of three others.
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rylated species of PLB as early as 30 s after addition of Ca2
and CaM. Increased phosphorylation was evident in both
sham and failure preparations but was more marked in the
latter (Fig. 3b). Addition of PKA and resultant serine phos-
phorylation of PLB appears to aid further phosphorylation by
a Ca2/CaM dependent kinase associated with the SR. This
corresponds with the increased levels of phosphorylation seen
in our previous studies examining intrinsic kinase activity as-
sociated with SR preparations from experimental hearts, par-
ticularly in freshly isolated left ventricular tissue that could
exhibit up to 10 di¡erent phosphorylated forms of PLB. The
fact that by stimulating serine phosphorylation above basal
levels (although not maximally) we were able to increase CaM
kinase activity suggests that there may be some degree of
dependency in how the SR kinase pathways are regulated.
Previous work by other groups has been contradictory in ex-
planation of how these pathways interact. Some suggest the
presence of dual control systems operating in an additive
manner to regulate SR function [15] whereas others disagree
with the idea of a coordinated dual control system and have
demonstrated that sequential phosphorylation has to occur
with threonine phosphorylation being dependent on prior ser-
ine phosphorylation [16]. This latter argument agrees with our
¢ndings in the present study, suggesting intrinsic SR CaM
kinase activity is boosted by the initial activation of PKA.
The use of inhibitors directed against CaM kinase II is
another way to highlight the involvement of this enzyme in
PLB phosphorylation in these studies. We have previously
used the inhibitor KN-62 [17] and found that even at maximal
doses (up to 10 WM) there was no speci¢c inhibition of rabbit
CaM kinase. In the present study we used a speci¢c peptide
inhibitor (281^309) which contains both the calmodulin bind-
ing site (290^309) and the autophosphorylation site (Thr-286/
7) of CaM kinase II. This inhibitor works by blocking Ca2/
CaM activation and the enzyme active site. Fig. 4. shows that
at 20 WM inhibitor, a maximal concentration still speci¢c for
CaM kinase, the upper phosphorylated band of PLB disap-
peared over time, indicating this inhibitor was preventing ac-
tivation of CaM kinase II and subsequent phosphorylation of
PLB in this rabbit SR preparation. It therefore seems likely
that the upper phosphorylated bands of PLB are a result of
CaM kinase II activation.
Further con¢rmation that the increase in phosphorylation
in experimental preparations may be due to an SR associated
CaM kinase was obtained by speci¢c strong positive staining
of 56^58 kDa bands in SR preparations that had been pre-
pared for electrophoresis (Fig. 5). This was observed using an
anti-N speci¢c antibody that had been raised against the C-
terminus of this subclass of CaM kinase [13]. These bands
correspond to distinct isoforms of N CaM kinase. Densitom-
etry analysis on sham and experimental preparations using
this antibody revealed increased expression of N CaM kinase
in experimental preparations by approximately 2.5-fold. This
is a similar value to the increased activity of CaM kinase
associated with these preparations observed in Fig. 2.
Additional immunoblotting experiments were performed on
the same preparations probing for Q CaM kinase. Using the
maximal concentration of this antibody recommended by the
suppliers, we could detect no evidence of the Q subclass in
either sham or experimental preparations (results not shown).
Very recent work by another group has suggested increased
transcript expression of N CaM kinase II in failing human
myocardium [18]. The present study strengthens this proposal
and for the ¢rst time, not only shows the presence of the N
isoform in rabbit myocardium, but also presents evidence for
increased expression of this protein in an animal model of
heart failure.
Previous studies have suggested that N CaM kinase is asso-
ciated with cardiac SR in other species, however, as far as we
are aware, there is only one indicating that the levels of this
enzyme may be altered under pathophysiological conditions in
the heart [18]. Evidence also exists however, for increased
CaM kinase II activity in rat hippocampus after long-term
ischaemia [19]. This is likely to be a di¡erent isoform. How-
ever, it highlights the possibility of up-regulation of CaM
kinase in diseased tissue. Although we have focused on PLB
phosphorylation by this enzyme, it is highly likely that other
substrates for this enzyme exist within the SR. It is possible
Fig. 4. E¡ect of CaM kinase II peptide inhibitor on intrinsic SR
kinase activity. SR preparations were incubated for the indicated
times as before in the presence of 2 mM ATP and the presence or
absence of the peptide (281^301) at 20 WM. Reactions were termi-
nated by the addition of 4ULaemmli sample bu¡er and subjected
to electrophoresis as described. PLB was detected with the A1 anti-
body. Results are from a single experiment, representative of two
others.
Fig. 5. Identi¢cation of N CaM kinase by immunoblot analysis. In-
creasing protein loads for SR preparations from hearts of sham-op-
erated and experimental animals were electrophoresed and probed
with a speci¢c rabbit anti-N CaM kinase antibody. Immunoblots
were developed and then subjected to densitometry analysis. Results
are expressed as optical density units and represent the mean þ
S.E.M. from a single typical experiment.
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that phosphorylation of PLB and other SR proteins that reg-
ulate Ca2 uptake and release will contribute to increased
myocardial relaxation. This would be particularly important
in heart failure when these mechanisms are impaired. Studies
by our group and others have suggested that the levels of PLB
and SERCA 2 are decreased in heart failure [7,20,21] and we
suggested that compensatory intracellular mechanisms may be
activated under these conditions. One such mechanism may
involve increased expression and/or activity of CaM kinase.
Other studies in rat cardiac myocytes and SR preparations
have suggested the existence of an SR kinase that is regulated
by lumenal Ca2 [22]. This ’state of ¢lling’ or SOF kinase
phosphorylates PLB when Ca2 is depleted in the SR, pro-
moting re¢lling of the Ca2 store. The identity of this kinase
is unknown, however, the regulatory principle behind activa-
tion may be similar to the kinase in the present study i.e.
under conditions where Ca2 uptake is limited, kinase activa-
tion promotes PLB phosphorylation, which in turn promotes
uptake by SERCA 2. As well as changes in kinase activities, it
seems possible that there will also be a corresponding change
in SR associated phosphatase levels. It has already been
shown that protein phosphatase 1 (PP1) has to be inhibited
to allow signi¢cant activation of CaM kinase [23]. PP1 de-
phosphorylates and deactivates CaM kinase and may well
a¡ect other SR related kinases. Already, drugs are being syn-
thesised that speci¢cally modulate certain signalling molecules
that have shown to be altered during heart failure [24,25].
Without doubt, the present studies will result in a clearer
understanding of how the functioning of the SR is altered
in failure. They may also create more scope for speci¢c ther-
apeutic modulation at a cellular or sub-cellular level with
advanced pharmacological or molecular tools.
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